AI Summary Avastin (bevacizumab) is a targeted therapy that blocks VEGF and is used with Tecentriq for unresectable or metastatic hepatocellular carcinoma.
Medically reviewed.
Avastin (bevacizumab) is a prescription targeted therapy used to treat several types of cancer, including advanced hepatocellular carcinoma (HCC) when it is combined with Tecentriq. It is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), a protein that promotes the growth of blood vessels that feed tumors. By reducing the blood supply to tumors, Avastin helps slow cancer growth and progression. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Avastin's role in liver cancer management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Avastin fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT AVASTIN TREATMENT
Avastin is a prescription medicine that contains bevacizumab, a type of medication known as a monoclonal antibody. It is a targeted therapy that blocks vascular endothelial growth factor (VEGF), a protein that helps tumors form new blood vessels.
Avastin is used to treat several types of cancer. In liver cancer, it is used for advanced hepatocellular carcinoma (HCC) when it is combined with Tecentriq (atezolizumab). This is systemic treatment, meaning medicine that travels through the whole body.
Avastin is given as ongoing therapy by a healthcare professional. Your care team monitors you regularly for bleeding, blood pressure changes, and protein in the urine.
WHO AVASTIN MAY BE SUITABLE FOR
Eligibility for Avastin depends on your diagnosis, the stage of your cancer, and your overall health. Your healthcare provider may prescribe Avastin if you have unresectable or metastatic hepatocellular carcinoma and you are receiving Tecentriq-based combination therapy. "Unresectable" means the cancer cannot be removed with surgery.
For people with advanced HCC and preserved liver function, atezolizumab (Tecentriq) plus bevacizumab (Avastin), or durvalumab plus tremelimumab, are preferred first-line options. People considered for atezolizumab plus bevacizumab should have an upper endoscopy to check for a high risk of bleeding.
Every patient's health profile is different. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, cancer stage, and treatment goals.
ELIGIBILITY OVERVIEW
Avastin may be considered for adults with the following conditions or treatment goals:
Before recommending Avastin, healthcare providers evaluate several factors to decide whether it is an appropriate option, including:
HOW AVASTIN CAN HELP WITH LIVER CANCER
Avastin blocks VEGF, a protein that promotes blood vessel formation. Tumors need new blood vessels to get the oxygen and nutrients they need to grow.
By blocking VEGF, Avastin reduces the blood supply to tumors. This helps slow tumor growth and progression. It also enhances the effectiveness of combination cancer therapies, which is why it is used with Tecentriq in advanced HCC.
For people with advanced liver cancer, these effects can support treatment goals such as controlling the disease and slowing its spread. Avastin is not used on its own for HCC. Your care team monitors you for bleeding, blood pressure changes, protein in the urine, and how well treatment is working.
LIVER CANCER BENEFITS
VEGF is a protein that promotes blood vessel formation, and tumors use it to build the blood supply that supports their growth. Avastin is a monoclonal antibody that blocks VEGF. Blocking the formation of new blood vessels is called anti-angiogenic therapy.
With fewer new blood vessels forming, less blood reaches the tumor. This helps slow tumor growth and progression. Avastin is a systemic treatment, so it works throughout the body. That is why it is used for unresectable or metastatic HCC, where surgery alone cannot remove the cancer.
Avastin enhances the effectiveness of combination cancer therapies. In advanced HCC, it is given with Tecentriq (atezolizumab), an immunotherapy that helps the immune system recognize and attack cancer cells. Avastin cuts the blood supply to the tumor while Tecentriq works on the immune response. This pairing is a first-line treatment for eligible people with advanced liver cancer, and the combination is commonly used for improved outcomes.
By slowing tumor growth and spread, Avastin helps control advanced liver cancer. It is given as ongoing therapy and continues until the disease progresses or side effects become unacceptable. Results vary from person to person, so your care team checks how well treatment is working as you go.
Avastin blocks VEGF to cut the blood supply that tumors need to grow. It is given with Tecentriq and should only be started and managed by a qualified healthcare professional.
TREATMENT PROCESS
Avastin is prepared and administered by a healthcare professional. You do not prepare it yourself.
The typical dose for hepatocellular carcinoma is 15 mg/kg every 3 weeks, in combination with Tecentriq. Your healthcare provider determines the right dose for you.
Avastin is given by intravenous (IV) infusion, following prescribing guidelines.
Avastin is used as ongoing systemic therapy in advanced liver cancer. It is continued until the disease progresses or side effects become unacceptable. Duration is individualized based on your response, how well you tolerate it, and your combination regimen.
Avastin is stored and handled by healthcare professionals.
Regular monitoring for bleeding, blood pressure changes, protein in the urine (proteinuria), and treatment response is recommended. Prompt reporting of abdominal pain or severe headaches is important.
BENEFITS AND SAFETY
Avastin may help people with advanced hepatocellular carcinoma by blocking the blood vessel growth that feeds tumors. This helps slow cancer growth and progression. It is used in combination with Tecentriq, a pairing that is commonly used for improved outcomes. The extent of benefit varies from person to person, depending on the cancer, overall health, and how the body tolerates treatment.
As with any medication, Avastin may cause side effects, including high blood pressure, fatigue, protein in the urine, bleeding events, and abdominal discomfort. Your healthcare provider will monitor you throughout treatment and assess whether Avastin remains a suitable option for you.
BENEFITS
Angiogenesis is the formation of new blood vessels. Avastin blocks the blood vessel formation that feeds tumors. Your provider may consider this approach when your cancer needs systemic treatment and you are a candidate for anti-angiogenic therapy.
By blocking VEGF, Avastin helps slow cancer growth and progression. The goal is to help control advanced liver cancer and slow tumor growth and spread. The extent of benefit varies from person to person.
Avastin is used with Tecentriq, an immunotherapy that helps the immune system attack cancer cells. The combination is commonly used for improved outcomes. It is a preferred first-line option for advanced HCC with preserved liver function.
Avastin is a monoclonal antibody that specifically targets VEGF signaling. During treatment, your care team monitors for bleeding, blood pressure changes, and protein in the urine, and checks how well treatment is working.
Report any signs of bleeding, unusual bruising, abdominal pain, or severe headaches to your care team promptly. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle habits are an important part of a comprehensive treatment plan alongside Avastin. Patients are advised to monitor blood pressure regularly, report signs of bleeding or unusual bruising, stay hydrated, manage fatigue with rest, and avoid activities that increase bleeding risk when advised.
A balanced, liver-friendly diet can also support your overall health. It is generally low in salt and sugar and built on whole grains, lean protein, fruits, and vegetables. Dietary needs vary by condition and stage, so ask your care team what fits you.
Areas that may support treatment:
common questions
Avastin may be an option if you have unresectable or metastatic hepatocellular carcinoma and are receiving Tecentriq-based combination therapy. "Unresectable" means surgery cannot remove the cancer. Your provider also looks at your cancer stage, liver function, overall health, and bleeding risk, which may include an upper endoscopy. Eligibility is individual, so talk with your healthcare provider or a liver specialist about whether Avastin fits your care plan.
Avastin is used with Tecentriq (atezolizumab) for advanced hepatocellular carcinoma, not on its own. Avastin blocks VEGF to cut the blood supply to tumors, while Tecentriq is an immunotherapy that helps the immune system attack cancer cells. Your healthcare provider decides whether this combination suits your cancer and how the two medicines are scheduled. Ask about the full treatment plan before you start.
Avastin is given by intravenous (IV) infusion, and a healthcare professional prepares and administers it. For hepatocellular carcinoma, the typical dose is 15 mg/kg every 3 weeks in combination with Tecentriq. You do not prepare or give it yourself. Your healthcare provider determines the right dose and schedule for you, so ask your care team what to expect at each visit.
Avastin helps slow tumor growth and progression in advanced liver cancer by blocking VEGF and reducing the blood supply to tumors. The combination with Tecentriq is commonly used for improved outcomes and is a preferred first-line option for advanced HCC with preserved liver function. Results vary from person to person, so discuss what to expect with your healthcare provider.
The common side effects of Avastin are high blood pressure, fatigue, protein in the urine, bleeding events, and abdominal discomfort. Your care team monitors for these throughout treatment. Report any bleeding, unusual bruising, abdominal pain, or severe headaches promptly. Your healthcare provider will discuss the potential benefits and risks with you before you start.
Avastin is continued until the disease progresses or side effects become unacceptable. It is ongoing systemic therapy, and the length of treatment is individualized based on your response, how well you tolerate it, and your combination regimen. Do not stop treatment on your own. Talk with your healthcare provider about how long you can expect to be on Avastin and when your plan will be reviewed.
Your care team regularly checks for bleeding, blood pressure changes, protein in the urine, and how well treatment is working. Monitoring continues throughout therapy. Lifestyle steps help too: check your blood pressure regularly, stay hydrated, rest when tired, and avoid activities that raise bleeding risk when advised. Ask your healthcare provider how often you will be checked and which tests you will have.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
